Overall survival (reported as mortality) · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower event‐free survival (reported as relapse, progressive disease,… compared with standard therapy (moderate certainty).
1 finding from 1 review
Early toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Late non‐haematological toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (reported as mortality) · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in overall survival (reported as mortality) compared with no further treatment (low certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in event‐free survival (reported as relapse, disease progression, death… compared with no further treatment (low certainty).
1 finding from 1 review
Early toxicity ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Late toxicity including secondary malignancies ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found